These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
204 related articles for article (PubMed ID: 36195739)
1. Evaluating the safety and efficacy of daprodustat for anemia of chronic kidney disease: a meta-analysis of randomized clinical trials. Fatima K; Ahmed W; Fatimi AS; Mahmud O; Mahar MU; Ali A; Aamir SR; Nasim MT; Islam MB; Maniya MT; Azim D; Marsia S; Almas T Eur J Clin Pharmacol; 2022 Dec; 78(12):1867-1875. PubMed ID: 36195739 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Daprodustat Vs rhEPO for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis. Fu Z; Geng X; Chi K; Song C; Wu D; Liu C; Hong Q Front Pharmacol; 2022; 13():746265. PubMed ID: 35359863 [No Abstract] [Full Text] [Related]
3. Efficacy and Safety of Daprodustat for Anemia Therapy in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. Zheng Q; Wang Y; Yang H; Sun L; Fu X; Wei R; Liu YN; Liu WJ Front Pharmacol; 2020; 11():573645. PubMed ID: 33597868 [No Abstract] [Full Text] [Related]
4. A randomized, 29-day, dose-ranging, efficacy and safety study of daprodustat, administered three times weekly in patients with anemia on hemodialysis. Bailey CK; Caltabiano S; Cobitz AR; Huang C; Mahar KM; Patel VV BMC Nephrol; 2019 Oct; 20(1):372. PubMed ID: 31619187 [TBL] [Abstract][Full Text] [Related]
5. Effect of daprodustat on anemia in patients with chronic kidney disease: a meta-analysis. Xie D; Wang J; Wu X; Li M Int Urol Nephrol; 2018 Dec; 50(12):2201-2206. PubMed ID: 30073615 [TBL] [Abstract][Full Text] [Related]
6. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors Yang J; Xing J; Zhu X; Xie X; Wang L; Zhang X Front Endocrinol (Lausanne); 2023; 14():1131516. PubMed ID: 37008953 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of daprodustat for patients on dialysis with anemia: systematic review and network meta-analysis. Ali Fadlalmola H; Al-Sayaghi KM; Al-Hebshi AA; Alhujaily M; Alyamani AO; Alem AA; Syrafi MH; Alem S; Farhat AH; Mohamed FA; Abdalrahman HH; Abdelmalik MA; Abdalrhman NM; Eltayeb AM Pan Afr Med J; 2024; 47():114. PubMed ID: 38828426 [TBL] [Abstract][Full Text] [Related]
11. Are there advantages of daprodustat over erythropoiesis-stimulating agents (ESAs) in treating anemia associated with chronic kidney disease (CKD)? Doggrell SA Expert Opin Pharmacother; 2022 May; 23(7):769-773. PubMed ID: 35380500 [TBL] [Abstract][Full Text] [Related]
12. Effects of Daprodustat, a Novel Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor on Anemia Management in Japanese Hemodialysis Subjects. Akizawa T; Tsubakihara Y; Nangaku M; Endo Y; Nakajima H; Kohno T; Imai Y; Kawase N; Hara K; Lepore J; Cobitz A Am J Nephrol; 2017; 45(2):127-135. PubMed ID: 27978511 [TBL] [Abstract][Full Text] [Related]
13. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients. Wang B; Yin Q; Han YC; Wu M; Li ZL; Tu Y; Zhou LT; Wei Q; Liu H; Tang RN; Cao JY; Lv LL; Liu BC Ren Fail; 2020 Nov; 42(1):912-925. PubMed ID: 32869703 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial. Singh AK; Cizman B; Carroll K; McMurray JJV; Perkovic V; Jha V; Johansen KL; Lopes RD; Macdougall IC; Obrador GT; Waikar SS; Wanner C; Wheeler DC; Wiecek A; Stankus N; Strutz F; Blackorby A; Cobitz AR; Meadowcroft AM; Paul G; Ranganathan P; Sedani S; Solomon S JAMA Intern Med; 2022 Jun; 182(6):592-602. PubMed ID: 35377393 [TBL] [Abstract][Full Text] [Related]
15. Long-term efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors in anaemia of chronic kidney disease: A meta-analysis including 13,146 patients. Chen H; Cheng Q; Wang J; Zhao X; Zhu S J Clin Pharm Ther; 2021 Aug; 46(4):999-1009. PubMed ID: 33615523 [TBL] [Abstract][Full Text] [Related]
16. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD. Gupta N; Wish JB Am J Kidney Dis; 2017 Jun; 69(6):815-826. PubMed ID: 28242135 [TBL] [Abstract][Full Text] [Related]
17. Changes in Iron Availability with Roxadustat in Nondialysis- and Dialysis-Dependent Patients with Anemia of CKD. Pergola PE; Charytan C; Little DJ; Tham S; Szczech L; Leong R; Fishbane S Kidney360; 2022 Sep; 3(9):1511-1528. PubMed ID: 36245647 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials. Provenzano R; Szczech L; Leong R; Saikali KG; Zhong M; Lee TT; Little DJ; Houser MT; Frison L; Houghton J; Neff TB Clin J Am Soc Nephrol; 2021 Aug; 16(8):1190-1200. PubMed ID: 34362786 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of HIF prolyl-hydroxylase inhibitor vs epoetin and darbepoetin for anemia in chronic kidney disease patients not undergoing dialysis: A network meta-analysis. Zheng Q; Yang H; Sun L; Wei R; Fu X; Wang Y; Huang Y; Liu YN; Liu WJ Pharmacol Res; 2020 Sep; 159():105020. PubMed ID: 32561478 [TBL] [Abstract][Full Text] [Related]
20. A 24-Week Anemia Correction Study of Daprodustat in Japanese Dialysis Patients. Tsubakihara Y; Akizawa T; Nangaku M; Onoue T; Yonekawa T; Matsushita H; Endo Y; Cobitz A Ther Apher Dial; 2020 Apr; 24(2):108-114. PubMed ID: 31306555 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]